China Oncology ›› 2022, Vol. 32 ›› Issue (9): 779-785.doi: 10.19401/j.cnki.1007-3639.2022.09.004

• Specialists' Commentary • Previous Articles     Next Articles

Advances in preclinical research models for gastroenteropancreatic neuroendocrine neoplasm

CUI Lingjun1,2(), TIAN Chao1,2, CHENG Zixuan1,2, ZHENG Jiabin2, SU Fei2, TAN Huangying2()   

  1. 1. Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China
    2. Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing 100029, China
  • Received:2022-07-01 Revised:2022-08-05 Online:2022-09-30 Published:2022-10-24
  • Contact: TAN Huangying

Abstract:

Gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) is a rare, heterogeneous tumor that can be divided into neuroendocrine tumor (NET) and neuroendocrine carcinoma (NEC) due to its degree of differentiation. With the gradual deepening of the exploration of its pathogenesis and treatment methods, the importance of preclinical models has become increasingly prominent. Here we reviewed the published preclinical models such as cell lines, organoid models, patient-derived xenograft models and genetically engineered mouse models. We also discussed the current practical applications of these models and their strengths and weaknesses, to provide threads and directions for future research.

Key words: Gastroenteropancreatic neuroendocrine neoplasm, Cell line, Organoid model, Patient-derived xenograft model, Genetically engineered mouse model

CLC Number: